Compare McKesson Corporation (MCK) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? McKesson Corporation trades at $941.12 (market cap $108.46B), while Direxion Daily S&P 500 Bull 3X Shares trades at $298 (market cap $7.36B). The key difference: McKesson Corporation is far larger — about 14.7× Direxion Daily S&P 500 Bull 3X Shares's market cap, and McKesson Corporation pays a 0.4% dividend while Direxion Daily S&P 500 Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Direxion Daily S&P 500 Bull 3X Shares for 32 Days on average.
| MCK | SPXL | |
|---|---|---|
Market Cap | $108.46B | $7.36B |
Volume | 712,607 | 1,835,467 |
Sector | Health | Leveraged / Inverse |
52-Week High | $995.69 | $301.38 |
52-Week Low | $725.17 | $170.20 |
Typical Hold Time | 74 Days | 32 Days |
Enterprise Value | $115.00B | — |
Dividend Yield | 0.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
SPXL trades at $298.10, up 0.42% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 66.91 suggesting mild overbought conditions. Recent news highlights S&P 500 valuation concerns despite strong earnings growth projections of 35% for 2026. The index faces concentration risks with top holdings accounting for 40% of value.
Outlook remains cautiously optimistic with seasonal patterns favoring year-end rallies, though profit growth is expected to slow to 15% in 2027. Key risks include market concentration, geopolitical uncertainty, and potential Fed policy impacts. Technical support at $289 and resistance at $300 will be critical near-term levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
